FDA Sets Meeting for Theravance Drug "WASHINGTON - A panel of government experts will meet in late February to review Theravance Inc.'s antibiotic to treat skin infections caused by 'superbug' bacteria. The Food and Drug Administration said its panel of antibiotic experts will meet Feb. 27 to consider approval of telavancin, which has already been delayed once by regulators."